X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (363) 363
humans (330) 330
diabetes mellitus, type 2 - drug therapy (268) 268
type 2 diabetes (257) 257
glucose-lowering drugs (226) 226
endocrinology & metabolism (221) 221
hypoglycemic agents - therapeutic use (213) 213
diabetes (202) 202
insulin (171) 171
male (159) 159
glucose (140) 140
female (139) 139
glycemic control (121) 121
diabetes mellitus (116) 116
middle aged (108) 108
hypoglycemic agents - administration & dosage (107) 107
dextrose (95) 95
aged (94) 94
metformin (90) 90
pharmacology & pharmacy (84) 84
diabetes therapy (83) 83
hypoglycemic agents - adverse effects (82) 82
mortality (81) 81
type 2 diabetes mellitus (81) 81
insulin - therapeutic use (79) 79
internal medicine (79) 79
treatment outcome (79) 79
animals (77) 77
diabetes mellitus, type 2 - blood (72) 72
blood glucose - metabolism (70) 70
risk factors (69) 69
risk (67) 67
to-target trial (67) 67
mellitus (65) 65
diabetes mellitus, type 2 - complications (62) 62
blood glucose - drug effects (61) 61
care and treatment (60) 60
medicine & public health (60) 60
hypoglycemic agents (59) 59
medicine, general & internal (59) 59
adult (58) 58
analysis (58) 58
cardiovascular disease (56) 56
hypoglycemia (56) 56
insulin glargine (56) 56
nph insulin (56) 56
hyperglycemia (55) 55
hypoglycemic agents - pharmacology (55) 55
type-2 diabetes-mellitus (55) 55
drug therapy (54) 54
cardiovascular outcomes (53) 53
insulin - administration & dosage (51) 51
therapy (50) 50
cardiac & cardiovascular systems (49) 49
glycated hemoglobin a - metabolism (49) 49
add-on (47) 47
clinical trials (47) 47
heart failure (47) 47
insulin - analogs & derivatives (47) 47
health aspects (45) 45
management (45) 45
metformin - therapeutic use (45) 45
basal insulin (44) 44
naive people (44) 44
heart-failure (43) 43
insulin detemir (43) 43
myocardial-infarction (41) 41
research (41) 41
rats (40) 40
double-blind (39) 39
review (39) 39
hypoglycemia - chemically induced (37) 37
diabetes mellitus, type 2 - metabolism (35) 35
drug therapy, combination (35) 35
cardiovascular diseases (34) 34
glucagon-like peptide-1 (34) 34
mice (34) 34
outcomes (34) 34
sulfonylurea compounds - therapeutic use (34) 34
diabetes mellitus, type 2 - epidemiology (33) 33
diabetics (32) 32
dipeptidyl peptidase-4 inhibitors (32) 32
drug administration schedule (32) 32
drugs (32) 32
glargine (31) 31
randomized controlled trials as topic (31) 31
association (30) 30
blood glucose - analysis (30) 30
metaanalysis (30) 30
metabolic diseases (30) 30
administration, oral (29) 29
glucose metabolism (29) 29
open-label (29) 29
safety (29) 29
abridged index medicus (28) 28
blood sugar (28) 28
disease (28) 28
dose-response relationship, drug (28) 28
endocrinology (28) 28
glucose-lowering agents (28) 28
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (553) 553
German (7) 7
Spanish (7) 7
Russian (5) 5
Japanese (2) 2
Chinese (1) 1
Korean (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Heart Journal, ISSN 0195-668X, 09/2015, Volume 36, Issue 34, pp. 2288 - 2296
Journal Article
Journal of the American Geriatrics Society, ISSN 0002-8614, 11/2018, Volume 66, Issue 11, pp. 2086 - 2091
OBJECTIVES To assess the risk of hospitalization for trauma associated with use of hypoglycemic glucose‐lowering drugs (GLDs) in individuals aged 65 and older.... 
trauma | glucose‐lowering drugs | older persons | diabetes | pharmacoepidemiology | glucose-lowering drugs | POPULATION | ADULTS | PROPENSITY SCORES | FRACTURE RISK | GERIATRICS & GERONTOLOGY | DIABETES-MELLITUS | EMERGENCY-DEPARTMENT | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DISEASE | GERONTOLOGY | COHORT | ASSOCIATION | Aged | Dextrose | Glucose | Hospitalization | Diabetes | Drug development | Insulin | Trauma | Cancer
Journal Article
FRONTIERS IN ENDOCRINOLOGY, ISSN 1664-2392, 01/2017, Volume 8, p. 6
Type 2 diabetes mellitus (T2DM) is a global pandemic, as evident from the global cartographic picture of diabetes by the International Diabetes Federation... 
clinical management | METFORMIN | insulin | GLUCOSE-LOWERING DRUGS | PATHOGENESIS | GLYCEMIA | DISEASE | ENDOCRINOLOGY & METABOLISM | primary care | CONSENSUS STATEMENT | diabetes | chronic | ASSOCIATION | Type 2 diabetes | Clinical trials | Hypoglycemic agents | Dosage and administration | Drug therapy | Methods
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 232 - 242
Journal Article
Diabetes Research and Clinical Practice, ISSN 0168-8227, 09/2019, Volume 155, p. 107785
The future of the newer classes of glucose-lowering drugs, namely dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists... 
Type 2 diabetes | Cardio-renal disease | Glucose-lowering agents | Outcome trials | Glycaemic control | KIDNEY-DISEASE | GLUCOSE-LOWERING DRUGS | CARDIOVASCULAR OUTCOMES | SAFETY | COMBINATION THERAPY | HEART-FAILURE | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | PIOGLITAZONE | GLUCAGON-LIKE PEPTIDE-1 | ENDOCRINOLOGY & METABOLISM | RENAL OUTCOMES
Journal Article
Pharmacological Reports, ISSN 1734-1140, 12/2015, Volume 67, Issue 6, pp. 1240 - 1250
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2017, Volume 120, Issue 1, pp. S17 - S27
Patients with type 2 diabetes (T2DM) have a significantly higher risk of developing cardiovascular disease (CVD)—namely myocardial infarction, heart failure,... 
Cardiovascular | VASCULAR-DISEASE PATHOPHYSIOLOGY | SULFONYLUREA DRUGS | CARDIAC & CARDIOVASCULAR SYSTEMS | GLUCAGON-LIKE PEPTIDE-1 | GLUCOSE-LOWERING DRUGS | SGLT2 INHIBITORS | HEART-FAILURE | RETROSPECTIVE EVALUATION | ACUTE MYOCARDIAL-INFARCTION | DPP-4 INHIBITORS | ACUTE CORONARY SYNDROME | Hypoglycemic Agents - therapeutic use | Thiazolidinediones - therapeutic use | Metformin - therapeutic use | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Sulfonylurea Compounds - therapeutic use | Diabetic Angiopathies - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Drugs | Heart failure | Periodical publishing | Hyperglycemia | Clinical trials | Insulin resistance | Product development | Glucose | Drug therapy | Cardiology | Health aspects | Dextrose | Mortality | Diabetes | Myocardial infarction | Heart | Intervention | Heart attacks | Peptides | Medical services | Risk | Cardiovascular disease | Prevention | Heart diseases | Hypertension | Cerebral infarction | Stroke | Complications | Pioglitazone | Diabetes mellitus | Health risks | Insulin | Patients | Morbidity | Sodium | Infarction | Acute coronary syndromes | Cardiovascular diseases
Journal Article
Biocatalysis and Biotransformation, ISSN 1024-2422, 01/2018, Volume 36, Issue 1, pp. 12 - 46
Journal Article